by Queen Mary, University of London A urine test that can detect early stage pancreatic cancer has reached the final stage of validation before being developed for use with patients. If successful, this non-invasive urine test would be the first in the world to help clinicians detect the highly lethal cancer at an early stage—enabling...
Tag: <span>Pancreatic cancer</span>
Post
Immunotherapy and Prevention of Pancreatic Cancer
Alexander H. Morrison | Katelyn T. Byrne | Robert H. Vonderheide HighlightsPancreatic cancer remains a lethal tumor that is difficult to treat and, unfortunately, immune therapies that have garnered FDA approval in other tumors have shown little efficacy to date in this tumor. These therapies include checkpoint antibodies and engineered T cell infusions. A formidable...
Post
Immune cell therapy shows early promise for patients with pancreatic cancer
by American Association for Cancer Research A non-engineered, multiantigen-specific T-cell therapy was safe, tolerable, and showed signs of clinical activity in patients who had pancreatic adenocarcinoma, according to preliminary results from a phase I clinical trial presented at the AACR special conference on Immune Cell Therapies for Cancer, held July 19–22. “Pancreatic adenocarcinoma is extremely...
Post
Compound puts pancreatic cancer in Immunotherapy’s sights
Nick Lavars Immunotherapy is a form of cancer treatment that seeks to supercharge the body’s natural immune defenses, and it’s become a viable therapy for certain types of the disease. Pancreatic cancer is one that has so far been able to evade its advances, but scientists are now reporting a discovery that might help the immune system regain the upper...
Post
Early research shows a way to develop effective therapies against pancreatic cancer
by Mariano Barbacid, The Conversation Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is the fifth most common cause of death from cancer in the UK and the third in the United States. Deaths from PDAC outnumber those from breast cancer despite the significant difference in incidence rates. Late diagnosis and ineffective treatments are the most important reasons for these bleak...
Post
Genomics Could Guide Pancreatic Cancer Treatment
Pancreatic cancer is a grim diagnosis, with a five-year survival rate of less than 9 percent. To improve those odds, researchersat UPMC and the University of Pittsburgh School of Medicine sought genetic signatures in the largest study of its kind that could be used to better match drugs to patients and for early detection. https: The Pancreas. Image credit: Blausen.com staff...
Post
Molecular envoys pave the way for pancreatic cancer to invade the liver
Pancreatic cancer usually spreads to the liver. The identification of signals from cells adjacent to pancreatic tumours that boost liver colonization might suggest ways to block this deadly form of cancer invasion. Pancreatic cancer is rapidly lethal, and the five-year post-diagnosis survival rate in the United States is 8%1. At diagnosis, the cancer has usually...
Post
Can the tongue microbiome help diagnose pancreatic cancer?
Pancreatic cancer is typically an aggressive form of the disease, with a fairly low 5-year survival rate. Diagnosing pancreatic cancer in its early stages could help people receive treatment more quickly, but what kind of test would work best? doctor examining tongue The specific bacterial abundance on a person’s tongue may indicate the presence of...
Post
VISTA checkpoint implicated in pancreatic cancer Immunotherapy resistance
Researchers have identified a new potential Immunotherapy target in pancreatic cancer, which so far has been notoriously resistant to treatment with immune checkpoint blockade drugs effective against a variety of other cancers. Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain. The University of Texas MD Anderson Cancer Center...
Post
Killer cell immunotherapy offers potential cure for advanced pancreatic cancer
A new approach to treating pancreatic cancer using ‘educated killer cells’ has shown promise, according to early research by Queen Mary University of London QUEEN MARY UNIVERSITY OF LONDON The new cell-based immunotherapy, which has not yet been tested in humans with pancreatic cancer, led to mice being completely cancer-free, including cancer cells that had already spread to the liver...